Skip to main content

Table 2 Clinical data of the colon cancer patients in ELISA study

From: Novel roles of DC-SIGNR in colon cancer cell adhesion, migration, invasion, and liver metastasis

Clinical data Cases Proportion sDC-SIGNR (ng/ml) median (range)
Gender
 Female 32 39.51% 72.88 (33.46–245.0)
 Male 49 60.49% 89.73 (26.81–249.3)
Age (year)
60 52 64.20% 62.25 (29.49–249.3)
 <60 29 35.80% 74.76 (26.81–245.0)
Stage
 I/II 20 24.69% 58.90 (29.49–140.0)
 III/IV 61 75.31% 70.97 (26.81–249.3)
Type of cancer
 Colon 42 51.85% 67.51 (33.83–249.3)
 Rectal 39 48.15% 66.53 (26.81–202.2)
Metastatic site
 No 20 24.69% 58.90 (29.49–140.0)
 Liver 33 40.74% 86.26 (33.83–202.2)
 Other 28 34.57% 59.71 (26.81–249.3)